Prestige Biopharma Limited

[On Demand]
Prestige BioPharma (PBP) is a Singapore-based biopharmaceutical company focusing on development of biosimilars and new antibody therapeutics. PBP has a strong footprint in the APAC region and is actively penetrating into the global pharmaceutical market.
The primary focus of current R&D is on oncology and immune disorders, developing new and biosimilar antibody drugs for solid tumors, pancreatic cancer, and arthritis. In parallel with our efforts to enhance safety, efficacy, and affordability of existing antibody therapeutics, PBP thrives to search for new targets and candidates to address unmet medical needs in oncology, immunology, degenerative & metabolic disorders.
Korea Exchange
Company Type:
Publicly Traded Company
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
HD201 (Trastuzumab biosimilar)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Head of Alliance Management
Prestige Biopharma Limited